Clinical trials: Major Depressive Disorder
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder
Spinal Cord Stimulation for the Treatment of Major Depressive Disorder
This pilot clinical trial will evaluate the efficacy and safety of transcutaneous direct current stimulation (tsDCS) in major depressive disorder.
- Trial name
- SPIDEP (NCT03433339)
- Testing
- Active transcutaneous spinal direct current stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01944969
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804270
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Paul E. Croarkin
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years.
- Trial name
- NCT03446846
- Testing
- MIN-117 5.0 mg, MIN-117 2.5 mg
- Where
- 47 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Minerva Neurosciences
Major Depressive Disorder
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
The purpose of this study is to evaluate the intermediate-term efficacy and tolerability of a multiple-dosing ketamine infusion paradigm for the treatment of medication-refractory major depressive disorder (MDD).
- Trial name
- SAD-KIDS (NCT03889756)
- Testing
- Ketamine infusion, Midazolam infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Reducing Internalized Stigma in People With Serious Mental Illness
The purpose of this study is to determine if Ending Self-Stigma (ESS), a 9-session group intervention designed to assist veterans with serious mental illness to develop skills (SMI) to effectively cope with stigma and minimize…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
- Trial name
- ESS (NCT01259427)
- Testing
- Ending Self Stigma (ESS), Health and Wellness Group
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder, Depression
Study to Treat Major Depressive Disorder (MDD) With a New Medication
The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD.
- Trial name
- NCT02149836
- Testing
- ezogabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
The purpose of this study is to see if using Cranial Electrical Stimulation (CES) helps improve symptoms of major depressive disorder (MDD).
- Trial name
- NCT01325532
- Testing
- Active CES
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Brain GABA Levels and Treatment Response in Major Depressive Disorder
This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00464711
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder, Major
The Role Of Omega-3 Fatty Acids In Adolescent Depression
The purpose of this study is to examine the effects of a 10-week Omega-3 Fatty Acid treatment phase on brain chemistry of adolescents with major depressive disorder (MDD) using proton magnetic resonance imaging.
- Trial name
- NCT00962598
- Testing
- Omega 3 Fatty Acids, Corn oil
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
MDD
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
This an open label study using a FDA-cleared TMS stimulation protocols which will be used to treat patients who have responded or remitted from depression using acute clinical TMS therapy at the University of Missouri-Columbia…
- Trial name
- NCT04076644
- Testing
- TMS treatment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Missouri-Columbia
Major Depressive Episode, Bipolar Depression
NeoSync TMS Treatment for Bipolar I Depression
This study is designed to evaluate the safety and preliminary efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Bipolar Disorder type I in a…
- Conditions
- Major Depressive Episode, Bipolar Depression, Bipolar Disorder, Mood Disorders
- Trial name
- NESTTBID (NCT02839798)
- Testing
- NEST (NeoSync EEG Synchronized TMS)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Butler Hospital
Major Depressive Disorder
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb).
- Trial name
- NCT00536471
- Testing
- Duloxetine hydrochloride
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 776 people
- Sponsor
- Eli Lilly and Company
Adjunctive Treatment of Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with…
- Trial name
- NCT03018340
- Testing
- Pimavanserin
- Where
- 36 sites in United States
- Volunteers
- 207 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Major Depressive Disorder
Biological Markers of Response to Treatment in Major Depressive Disorder
The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or…
- Trial name
- NCT00361218
- Testing
- open-label selective serotonin reuptake inhibitor (SSRI)
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder (MDD)
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs.
- Trial name
- NCT02015546
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University